These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24327714)

  • 1. T-DM1 aids patients with advanced breast cancer.
    Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
    [No Abstract]   [Full Text] [Related]  

  • 2. T-DM1 Extends Survival in HER2+ Breast Cancer.
    Cancer Discov; 2016 Feb; 6(2):OF4. PubMed ID: 26676162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
    Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
    J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
    Bourdeanu L; Luu T
    Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
    Mathew J; Perez EA
    Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 10. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
    Noguchi E; Shimizu C
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
    de Vries CL; Linn SC; Brandsma D
    J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.
    Shen K; Ma X; Zhu C; Wu X; Jia H
    Sci Rep; 2016 Mar; 6():23262. PubMed ID: 26979925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
    Lianos GD; Roukos DH
    Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597
    [No Abstract]   [Full Text] [Related]  

  • 15. Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate.
    Cancer Discov; 2016 Feb; 6(2):OF3. PubMed ID: 26701087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoconjugates in the treatment of breast cancer.
    Tripathy D
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):469-72. PubMed ID: 25322329
    [No Abstract]   [Full Text] [Related]  

  • 17. Breakthrough in breast cancer treatment. "Smart bullet" T-DM1 delivers a payload to cancer cells and avoids healthy ones.
    Duke Med Health News; 2012 Aug; 18(8):3. PubMed ID: 23029673
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 19. T-DM1 for HER2-positive metastatic breast cancer.
    Yaqub F
    Lancet Oncol; 2013 Mar; 14(3):e94. PubMed ID: 23580966
    [No Abstract]   [Full Text] [Related]  

  • 20. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
    Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
    Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.